Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16955968rdf:typepubmed:Citationlld:pubmed
pubmed-article:16955968lifeskim:mentionsumls-concept:C0003280lld:lifeskim
pubmed-article:16955968lifeskim:mentionsumls-concept:C0026457lld:lifeskim
pubmed-article:16955968lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:16955968lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:16955968lifeskim:mentionsumls-concept:C0439852lld:lifeskim
pubmed-article:16955968pubmed:issue1-2lld:pubmed
pubmed-article:16955968pubmed:dateCreated2006-9-7lld:pubmed
pubmed-article:16955968pubmed:abstractTextThe combinations of some anticoagulants (phenindione, chlorphenadione, diphenadione, phenprocoumon, 3-[1-(p-chlorophenyl)propyl]-4-hydroxycoumarin, cumachlor and acenocoumarol) with MAO-inhibitors (phenylcyclopropylamino hydrochloride, isocarboxazid, iproniazid, nialamide and p-chloro-N'-[2-(isopropylcarbamoyl)-1-methylethyl]benzohydrazide) were investigated with regard to modification of the anticoagulant activity in the rat. The activity of some anticoagulants like phenindione may be enhanced by the addition of MAO-inhibitors, whereas others (chlorphenadione, phenprocoumon) are only slightly or not at all influenced. The MAO-inhibitors phenylcyclopropylamino hydrochloride and nialamide show enhancement of activity in most combinations whereas iproniazid never does. The other MAO-inhibitors lie between these two extremes.lld:pubmed
pubmed-article:16955968pubmed:languagegerlld:pubmed
pubmed-article:16955968pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16955968pubmed:citationSubsetIMlld:pubmed
pubmed-article:16955968pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16955968pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16955968pubmed:statusMEDLINElld:pubmed
pubmed-article:16955968pubmed:monthSeplld:pubmed
pubmed-article:16955968pubmed:issn0340-5338lld:pubmed
pubmed-article:16955968pubmed:authorpubmed-author:ReberKKlld:pubmed
pubmed-article:16955968pubmed:authorpubmed-author:StuderAAlld:pubmed
pubmed-article:16955968pubmed:issnTypePrintlld:pubmed
pubmed-article:16955968pubmed:day1lld:pubmed
pubmed-article:16955968pubmed:volume14lld:pubmed
pubmed-article:16955968pubmed:ownerNLMlld:pubmed
pubmed-article:16955968pubmed:authorsCompleteYlld:pubmed
pubmed-article:16955968pubmed:pagination83-7lld:pubmed
pubmed-article:16955968pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16955968pubmed:meshHeadingpubmed-meshheading:16955968...lld:pubmed
pubmed-article:16955968pubmed:meshHeadingpubmed-meshheading:16955968...lld:pubmed
pubmed-article:16955968pubmed:meshHeadingpubmed-meshheading:16955968...lld:pubmed
pubmed-article:16955968pubmed:meshHeadingpubmed-meshheading:16955968...lld:pubmed
pubmed-article:16955968pubmed:meshHeadingpubmed-meshheading:16955968...lld:pubmed
pubmed-article:16955968pubmed:meshHeadingpubmed-meshheading:16955968...lld:pubmed
pubmed-article:16955968pubmed:year1965lld:pubmed
pubmed-article:16955968pubmed:articleTitle[Effect of the activity of an indirect anticoagulant by a monoamine oxidase inhibitor].lld:pubmed
pubmed-article:16955968pubmed:affiliationAbteilung für experimentelle Medizin der F. Hoffmann-La Roche & Co. AG., Basel.lld:pubmed
pubmed-article:16955968pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16955968pubmed:publicationTypeEnglish Abstractlld:pubmed